logo1
CNBC interview with Galapagos CEO Onno van de Stolpe
April 27, 2005 13:54 ET | Galapagos NV
Not for release, publication or distribution in or into the United States, Canada, Australia, Japan or any other jurisdiction where this is not allowed pursuant to local legal...
logo1
Cystic Fibrosis Foundation Therapeutics and Galapagos Initiate Galapagos Initiate Alliance to Discover Drug Targets
April 14, 2005 01:23 ET | Galapagos NV
"We are excited about this opportunity to apply our adenoviral collections and screening expertise to CFFT's target discovery program," said Onno van de Stolpe, CEO of Galapagos. "The fact that...
logo1
Galapagos appoints Andre Hoekema as Managing Director Galadeno
April 12, 2005 05:00 ET | Galapagos NV
"We are very pleased to have someone of Andre's caliber lead our services unit," commented Onno van de Stolpe, CEO of Galapagos. "Andre brings to Galapagos a vast experience in the biotech industry...
logo1
Staf Van Reet to lead Galapagos Corporate Development
March 31, 2005 05:00 ET | Galapagos NV
"We are very pleased to welcome Staf Van Reet on board during this exciting time for Galapagos," commented Onno van de Stolpe, CEO of Galapagos. "Staf's many years of experience in the successful...
logo1
TNO AND GALAPAGOS ENTER INTO DRUG TARGET CHARACTERIZATION COLLABORATION
March 29, 2005 01:00 ET | Galapagos NV
The project is part of a research program sponsored by the Dutch government through SenterNovem and will combine the capabilities and know-how of TNO and Galapagos to develop protein technologies that...
logo1
GALAPAGOS IS CONSIDERING A STOCK EXCHANGE LISTING
March 09, 2005 03:36 ET | Galapagos NV
Galapagos has already successfully discovered and validated novel targets in these bone and joint diseases, as well as in its asthma and Alzheimer's disease programs. Moreover, Galapagos recently...
logo1
GALAPAGOS IS CONSIDERING A STOCK EXCHANGE LISTING
March 09, 2005 03:12 ET | Galapagos NV
Galapagos has already successfully discovered and validated novel targets in these bone and joint diseases, as well as in its asthma and Alzheimer's disease programs. Moreover, Galapagos recently...
logo1
Boehringer Ingelheim Licenses Results from Target Discovery Collaboration with Galapagos
January 20, 2005 02:00 ET | Galapagos NV
The SilenceSelectTM collection is offered by Galádeno, Galapagos' genomics services unit. The adenoviral collection contains siRNA knock-down sequences targeting over 4,000 human drugable transcripts,...
logo1
GlaxoSmithKline forms Target Discovery Alliance in Asthma with Galapagos
January 05, 2005 08:00 ET | Galapagos NV
"We are excited that we have now partnered our asthma program with the leading player in this disease area" said Onno van de Stolpe, CEO of Galapagos. "The licensing of our targets to GSK is a...
logo1
Graham Dixon joins Galapagos as Chief Scientific Officer
November 30, 2004 02:00 ET | Galapagos NV
About Galapagos Genomics NVGalapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma.  Proprietary...